 - Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting - - Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 -- Cash burn rate steady -- Cash and Cash Equivalents of 15. 